These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32869110)

  • 21. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 22. Defining "innovativeness" in drug development: a systematic review.
    Kesselheim AS; Wang B; Avorn J
    Clin Pharmacol Ther; 2013 Sep; 94(3):336-48. PubMed ID: 23722626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use.
    Daniel GW; Cazé A; Romine MH; Audibert C; Leff JS; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):319-27. PubMed ID: 25646113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A measure of productivity and innovation in the pharmaceutical industry 2011-2015.
    Harrison R
    Drugs Today (Barc); 2016 Nov; 52(11):627-633. PubMed ID: 28112281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical innovation and access to financial markets.
    Blau BM; Griffith TG; Whitby RJ
    PLoS One; 2022; 17(12):e0278875. PubMed ID: 36538526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Market entry, power, pharmacokinetics: what makes a successful drug innovation?
    Alt S; Helmstädter A
    Drug Discov Today; 2018 Feb; 23(2):208-212. PubMed ID: 28939470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projecting future drug expenditures--2003.
    Shah ND; Hoffman JM; Vermeulen LC; Hunkler RJ; Hontz KM
    Am J Health Syst Pharm; 2003 Jan; 60(2):137-49. PubMed ID: 12561658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stategic trends in the drug industry.
    Drews J
    Drug Discov Today; 2003 May; 8(9):411-20. PubMed ID: 12706659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Public policy and pharmaceutical innovation.
    Grabowski HG
    Health Care Financ Rev; 1982 Sep; 4(1):75-87. PubMed ID: 10309721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicine and pharmacy--facts and myths about the development of an innovative pharmaceutical industry in Poland.
    Kubiak W
    Sci Eng Ethics; 2005 Jan; 11(1):41-51. PubMed ID: 15726998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaceutical sector in transition--a cross sectional study in Vietnam.
    Falkenberg T; Nguyen TB; Larsson M; Nguyen TD; Tomson G
    Southeast Asian J Trop Med Public Health; 2000 Sep; 31(3):590-7. PubMed ID: 11289028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Approach to Assessing the Innovativeness of New Drugs Finds Accelerating Rate of Innovation.
    Wills TJ; Lipkus AH
    ACS Med Chem Lett; 2020 Nov; 11(11):2114-2119. PubMed ID: 33209190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
    D'Este P; Tribó JA; García-Romero A
    Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel medicines marketed in the UK (1960-87).
    Lis Y; Walker SR
    Br J Clin Pharmacol; 1989 Sep; 28(3):333-43. PubMed ID: 2789928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
    Lichtenberg FR
    Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.